Results 111 to 120 of about 97,449 (305)

Engineered Microfluidic Organoid Systems: New Paradigms for Menopause Mechanism Research and Personalized Medicine

open access: yesAdvanced Materials Technologies, EarlyView.
This review explores the integration of microfluidic technology with organoid systems as an innovative platform for studying menopausea complex multi‐organ condition. By enabling precise simulation of inter‐organ communication and hormone responses, microfluidic organoids offer a physiologically relevant model for investigating menopausal syndrome and ...
Qianyi Zhang   +4 more
wiley   +1 more source

High-grade serous carcinoma of unknown primary origin associated with STIC clinically presented as isolated inguinal lymphadenopathy: a case report

open access: yesFrontiers in Oncology
Serous tubal intraepithelial carcinoma (STIC) is a precancerous lesion of high-grade serous ovarian carcinoma (HGSOC). Usually, it arises from the fimbrial end of the tube, and it is associated with metastatic potential.
Paola Giancontieri   +7 more
doaj   +1 more source

Low-grade mucinous appendiceal neoplasm mimicking an ovarian lesion: A case report and review of literature. [PDF]

open access: yesWorld J Clin Cases, 2021
Borges AL   +4 more
europepmc   +1 more source

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. [PDF]

open access: yes, 2015
BackgroundThis first-in-human study evaluated AMG 208, a small-molecule MET inhibitor, in patients with advanced solid tumors.MethodsThree to nine patients were enrolled into one of seven AMG 208 dose cohorts (25, 50, 100, 150, 200, 300, and 400 mg ...
Amore, Benny   +14 more
core   +2 more sources

Cross‐Scale Hierarchical Targeted Delivery System Based on Small‐Scale Magnetic Robots

open access: yesAdvanced Robotics Research, EarlyView.
This article reviews a cross‐scale hierarchical targeted delivery system that integrates magnetic continuum robots and magnetic microrobots. By combining rapid long‐range navigation with precise microscale targeting, the system overcomes key limitations of single‐scale approaches.
Junjian Zhou   +4 more
wiley   +1 more source

Inflammation targets specific organs for cancer in carriers of BRCA1/2 pathway mutations [PDF]

open access: yes, 2010
Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast/ovarian cancer that are so high and apparently so selective that many mutation carriers choose to have the most likely targets for cancer surgically removed.
Bernard Friedenson
core   +1 more source

Ovarian lesions in 44 rabbits (Oryctolagus cuniculus).

open access: yesThe Journal of veterinary medical science, 2017
The clinical and pathological records of 44 domestic, female rabbits with an age ranging from 6-124 months (median age: 63.5 month) were assessed retrospectively for ovarian lesions. Included were all rabbits that underwent an ovariohysterectomy with a subsequent pathological examination of the genital tract between March 1997 and June 2016 ...
BERTRAM, Christof Albert   +2 more
openaire   +2 more sources

Integrated Transcriptomics Reveals Evolutionary Trajectories and Cell Density‐Dependent Mechanisms in Aldosterone‐Producing Adenomas

open access: yesAdvanced Science, EarlyView.
Aldosterone‐producing adenomas (APAs) develop via two distinct paths: directly from adrenal zona glomerulosa (zG) cells, or stepwise from zG cells through aldosterone‐producing micronodules (APMs) before progressing to APAs. Advanced single‐cell and spatial analyses identified distinct cell states linked to oxidative stress and cell–cell interactions ...
Zhuolun Sun   +7 more
wiley   +1 more source

HISTOPATHOLOGICAL STUDY OF OVARIAN CYSTIC LESIONS

open access: yesJournal of Saidu Medical College, Swat, 1969
BACKGROUND: Ovarian cystic lesions are common in gynecologic practice and is the most commoncause of gynecologic surgery in hospitals. These may be non neoplastic or neoplastic. The neoplasticmay be either benign or malignant. It is clinically important to differentiate between benign andmalignant cystic lesions for management purpose.OBJECTIVE: To ...
null SANIA TANWEER KHATTAK   +4 more
openaire   +2 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy